BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vieira-martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-bacchi V. Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science 2016;54:212-9. [DOI: 10.1016/j.transci.2016.04.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 El Karoui K, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J, Aulagnon F, Matignon M, Rondeau E, Mesnard L, Halimi JM, Frémeaux-Bacchi V. Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica 2019;104:2501-11. [PMID: 30890598 DOI: 10.3324/haematol.2019.216903] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
2 Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, Coucelo M, Manco L, Maia T, Mendes MJ, Del Orbe Barreto R, Corrales I, Vidal F, Ribeiro ML. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost 2017;1:69-80. [PMID: 30046676 DOI: 10.1002/rth2.12016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
3 Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2019;30:2449-63. [PMID: 31575699 DOI: 10.1681/ASN.2019040331] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
4 Hevey R, Pouw RB, Harris C, Ricklin D. Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. Br J Pharmacol 2021;178:2802-22. [PMID: 33140840 DOI: 10.1111/bph.15307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
6 Lumbreras J, Subias M, Espinosa N, Ferrer JM, Arjona E, Rodríguez de Córdoba S. The Relevance of the MCP Risk Polymorphism to the Outcome of aHUS Associated With C3 Mutations. A Case Report. Front Immunol 2020;11:1348. [PMID: 32765494 DOI: 10.3389/fimmu.2020.01348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Matsumoto T, Toyoda H, Amano K, Hirayama M, Ishikawa E, Fujimoto M, Ito M, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Kawamura N, Ikejiri M, Kawakami K, Miyata T, Wada H. Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan. Clin Appl Thromb Hemost 2018;24:1301-7. [PMID: 29695177 DOI: 10.1177/1076029618771750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
8 Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1719-32. [PMID: 31694864 DOI: 10.2215/CJN.05830519] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
9 Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. Pediatr Nephrol 2018;33:1437-42. [PMID: 29728803 DOI: 10.1007/s00467-018-3957-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens: Meta-Analysis of Atypical HUS Case Reports. Therapeutic Apheresis and Dialysis 2018;22:178-88. [DOI: 10.1111/1744-9987.12641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
11 Platt JL, Cascalho M, Piedrahita JA. Xenotransplantation: Progress Along Paths Uncertain from Models to Application. ILAR J. 2018;59:286-308. [PMID: 30541147 DOI: 10.1093/ilar/ily015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Claes KJ, Massart A, Collard L, Weekers L, Goffin E, Pochet JM, Dahan K, Morelle J, Adams B, Broeders N, Stordeur P, Abramowicz D, Bosmans JL, Van Hoeck K, Janssens P, Pipeleers L, Peeters P, Van Laecke S, Levtchenko E, Sprangers B, van den Heuvel L, Godefroid N, Van de Walle J. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg. 2018;73:80-89. [PMID: 29058539 DOI: 10.1080/17843286.2017.1345185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. [PMID: 27799617 DOI: 10.2215/CJN.06440616] [Cited by in Crossref: 94] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
14 Coelho Júnior JL, Israel KCP, Machado CEE, Muniz MPR, Gatto GC, Barros FHS, Cunha KA, de Lacerda MVG, Neves PDMM, Silva GEB. Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases. PLoS Negl Trop Dis 2021;15:e0009790. [PMID: 34648498 DOI: 10.1371/journal.pntd.0009790] [Reference Citation Analysis]
15 Badiola J, Navarrete-Navarrete N, Sabio JM. Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. Rheumatol Int 2019;39:359-65. [PMID: 30554307 DOI: 10.1007/s00296-018-4228-5] [Reference Citation Analysis]
16 Barnum SR. Complement: A primer for the coming therapeutic revolution. Pharmacol Ther 2017;172:63-72. [PMID: 27914981 DOI: 10.1016/j.pharmthera.2016.11.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
17 J C, Am K, R S, Morris G, P B, Md S, Ds A. Systematic scoping review of studies reporting unexpected donor-derived abnormalities from recipients of allogeneic hematopoietic cell transplantation: a proposed framework for donor disclosure: donor-derived abnormalities in allogeneic HCT. Transplant Cell Ther 2022:S2666-6367(22)01191-5. [PMID: 35398578 DOI: 10.1016/j.jtct.2022.03.029] [Reference Citation Analysis]
18 Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V; Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018;94:408-18. [PMID: 29907460 DOI: 10.1016/j.kint.2018.02.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 12.8] [Reference Citation Analysis]
19 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
20 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
21 Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
23 Goel A, Ramakrishna B, Zachariah U, Sajith KG, Burad DK, Kodiatte TA, Keshava SN, Balasubramanian KA, Elias E, Eapen CE. What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors. Indian J Med Res 2019;149:468-78. [PMID: 31411170 DOI: 10.4103/ijmr.IJMR_1405_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 2018;33:2009-25. [PMID: 28884355 DOI: 10.1007/s00467-017-3783-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
25 Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol 2019;10:1157. [PMID: 31258525 DOI: 10.3389/fimmu.2019.01157] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
26 Wu H, Su S, Li L, Zhang L. Atypical hemolytic uremic syndrome and acute tubular necrosis induced by complement factor B gene (CFB) mutation: A case report. Medicine (Baltimore) 2021;100:e25069. [PMID: 33725982 DOI: 10.1097/MD.0000000000025069] [Reference Citation Analysis]
27 Gulati A, Somlo S. Whole exome sequencing: a state-of-the-art approach for defining (and exploring!) genetic landscapes in pediatric nephrology. Pediatr Nephrol 2018;33:745-61. [PMID: 28660367 DOI: 10.1007/s00467-017-3698-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gomez-Ganda L, Benitez-Carabante MI, Fernandez-Polo A, Muñoz-Lopez M, Renedo-Miro B, Ariceta G, Diaz De Heredia C. Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy. Front Pediatr 2021;9:761726. [PMID: 34858907 DOI: 10.3389/fped.2021.761726] [Reference Citation Analysis]
29 Münch J, Bachmann A, Grohmann M, Mayer C, Kirschfink M, Lindner TH, Bergmann C, Halbritter J. Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies. Clin Kidney J 2017;10:742-6. [PMID: 29225802 DOI: 10.1093/ckj/sfx053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
30 Wong MD, Patel C, McTaggart S, Wainwright CE. Atypical haemolytic uraemic syndrome in a child with cystic fibrosis. J Paediatr Child Health 2021. [PMID: 34008207 DOI: 10.1111/jpc.15571] [Reference Citation Analysis]
31 Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15:312-22. [PMID: 27868334 DOI: 10.1111/jth.13571] [Cited by in Crossref: 190] [Cited by in F6Publishing: 171] [Article Influence: 38.0] [Reference Citation Analysis]